Practical applications for epigenetic biomarkers in cancer diagnostics

Expert Opinion on Medical Diagnostics

Volumn 1, Issue 1, 2007, Pages 17-30

  Rivenbark, Ashley G ^a   Coleman, William B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cancer screening; DNA methylation; epigenetic biomarker

Indexed keywords

EID: 80052131644     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.1.1.17     Document Type: Review

References (125)

1. WEINBERG RA: Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res. (1989) 49: 3713-3721. (Pubitemid 19197385)
2. BISHOP JM: Molecular themes in oncogenesis. Cell (1991) 64: 235-248.
3. FEINBERG AP: The epigenetics of cancer etiology. Semin. Cancer Biol. (2004) 14: 427-432. (Pubitemid 39360990)
4. DUCASSE M, BROWN MA: Epigenetic aberrations and cancer. Mol. Cancer (2006) 5: 60.
5. BAYLIN SB: DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. (2005) 2: S4-S11. (Pubitemid 43135229)
6. YAN PS, VENKATARAMU C, IBRAHIM A et al.: Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin. Cancer Res. (2006) 12: 6626-6636. (Pubitemid 44876830)
7. DONSON AM, ADDO-YOBO SO, HANDLER MH et al.: MGMT promoter methylation correlates with survival benefi t and sensitivity to temozolomide in pediatric glioblastoma. Pediatr. Blood Cancer (2007) 48: 403-407. (Pubitemid 46340105)
8. ABE M, WESTERMANN F, NAKAGAWARA A et al.: Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett. (2007) 247: 253-258. (Pubitemid 46240612)
9. WIDSCHWENDTER M, JONES PA: DNA methylation and breast carcinogenesis. Oncogene (2002) 21: 5462-5482. (Pubitemid 34983482)
10. JONES PA, TAKAI D: The role of DNA methylation in mammalian epigenetics. Science (2001) 293: 1068-1070. (Pubitemid 32758075)
11. TAKAI D, JONES PA: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA (2002) 99: 3740-3745. (Pubitemid 34252176)
12. BIRD AP: CpG-rich islands and the function of DNA methylation. Nature (1986) 321: 209-213. (Pubitemid 16016411)
13. GARDINER-GARDEN M, FROMMER M: CpG islands in vertebrate genomes. J. Mol. Biol. (1987) 196: 261-282. (Pubitemid 17122132)
14. RAZIN A, RIGGS AD: DNA methylation and gene function. Science (1980) 210: 604-610.
15. RAZIN A, SZYF M: DNA methylation patterns. Formation and function. Biochim. Biophys. Acta (1984) 782: 331-342.
16. JONES PA: The DNA methylation paradox. Trends Genet. (1999) 15: 34-37. (Pubitemid 29207343)
17. HERMAN JG, BAYLIN SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. (2003) 349: 2042-2054. (Pubitemid 37448928)
18. BAYLIN S: DNA methylation and epigenetic mechanisms of carcinogenesis. Dev. Biol. (Basel) (2001) 106: 85-87.
19. BAYLIN SB, HERMAN JG, GRAFF JR et al.: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. (1998) 72: 141-196. (Pubitemid 27435555)
20. MOMPARLER RL: Cancer epigenetics. Oncogene (2003) 22: 6479-6483. (Pubitemid 37372327)
21. JONES PA, LAIRD PW: Cancer epigenetics comes of age. Nat. Genet. (1999) 21: 163-167. (Pubitemid 29070360)
22. TSOU JA, HAGEN JA, CARPENTER CL et al.: DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene (2002) 21: 5450-5461. (Pubitemid 34983481)
23. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100: 57-70. (Pubitemid 30046295)
24. BAYLIN SB, OHM JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer (2006) 6: 107-116. (Pubitemid 43361543)
25. JOHNSON PJ, LO YM: Plasma nucleic acids in the diagnosis and management of malignant disease. Clin. Chem. (2002) 48: 1186-1193. (Pubitemid 34809823)
26. FLEISCHHACKER M, SCHMIDT B: Circulating nucleic acids (CNAs) and cancer-a survey. Biochim. Biophys. Acta (2007) 1775: 181-232. (Pubitemid 44911084)
27. ZHU J, YAO X: Use of DNA methylation for cancer detection and molecular classification. J. Biochem. Mol. Biol. (2007) 40: 135-141. (Pubitemid 46515190)
28. PALUSZCZAK J, BAER-DUBOWSKA W: Epigenetic diagnostics of cancer-the application of DNA methylation markers. J. Appl. Genet. (2006) 47: 365-375. (Pubitemid 44893733)
29. COTTRELL SE: Molecular diagnostic applications of DNA methylation technology. Clin. Biochem. (2004) 37: 595-604. (Pubitemid 38845022)
30. ZIEGLER A, ZANGEMEISTER-WITTKE U, STAHEL RA: Circulating DNA: a new diagnostic gold mine? Cancer Treat. Rev. (2002) 28: 255-271. (Pubitemid 35439439)
31. JAHR S, HENTZE H, ENGLISCH S et al.: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. (2001) 61: 1659-1665. (Pubitemid 34292602)
32. LAIRD PW: The power and the promise of DNA methylation markers. Nat. Rev. Cancer (2003) 3: 253-266. (Pubitemid 37328861)
33. GONZALGO ML, LIANG G, SPRUCK CH III et al.: Identification and characterization of differentially methylated regions of genomic DNA by methylationsensitive arbitrarily primed PCR. Cancer Res. (1997) 57: 594-599. (Pubitemid 27085638)
34. TOYOTA M, HO C, AHUJA N et al.: Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. (1999) 59: 2307-2312. (Pubitemid 29242273)
35. HAYASHIZAKI Y, HIROTSUNE S, OKAZAKI Y et al.: Restriction landmark genomic scanning method and its various applications. Electrophoresis (1993) 14: 251-258. (Pubitemid 23147986)
36. HUANG TH, PERRY MR, LAUX DE: Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. (1999) 8: 459-470. (Pubitemid 29097334)
37. FROMMER M, MCDONALD LE, MILLAR DS et al.: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad Sci. USA (1992) 89: 1827-1831.
38. GITAN RS, SHI H, CHEN CM et al.: Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res. (2002) 12: 158-164. (Pubitemid 34065599)
39. EADS CA, DANENBERG KD, KAWAKAMI K et al.: CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. (1999) 59: 2302-2306. (Pubitemid 29242272)
40. EADS CA, DANENBERG KD, KAWAKAMI K et al.: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. (2000) 28: E32.
41. COTTRELL SE, LAIRD PW: Sensitive detection of DNA methylation. Ann. NY Acad Sci. (2003) 983: 120-130. (Pubitemid 36399325)
42. COTTRELL SE, DISTLER J, GOODMAN NS et al.: A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res. (2004) 32: E10.
43. MIYAMOTO K, USHIJIMA T: Diagnostic and therapeutic applications of epigenetics. Jpn. J. Clin. Oncol. (2005) 35: 293-301. (Pubitemid 41444276)
44. HA PK, CALIFANO JA: Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol. (2006) 7: 77-82. (Pubitemid 43025396)
45. DUENAS-GONZALEZ A, LIZANO M, CANDELARIA M et al.: Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol. Cancer. (2005) 4: 38.
46. BALCH C, HUANG TH, BROWN R et al.: The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. (2004) 191: 1552-1572. (Pubitemid 39491180)
47. VAN DOORN R, GRUIS NA, WILLEMZE R et al.: Aberrant DNA methylation in cutaneous malignancies. Semin. Oncol. (2005) 32: 479-487. (Pubitemid 41396425)
48. KUROKI T, TAJIMA Y, KANEMATSU T: Role of hypermethylation on carcinogenesis in the pancreas. Surg. Today (2004) 34: 981-986. (Pubitemid 40104546)
49. DEBINSKI W, GIBO D, MINTZ A: Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors. Ann. NY Acad Sci. (2003) 983: 232-242. (Pubitemid 36399336)
50. CLAUS R, ALMSTEDT M, LUBBERT M: Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin. Oncol. (2005) 32: 511-520. (Pubitemid 41396428)
51. KAY PH, SPAGNOLO DV, TAYLOR J et al.: DNA methylation and developmental genes in lymphomagenesis-more questions than answers? Leuk. Lymphoma. (1997) 24: 211-220. (Pubitemid 27101593)
52. JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics 2007. CA Cancer J. Clin. (2007) 57: 43-66.
53. MIELNICKI LM, ASCH HL, ASCH BB: Genes, chromatin, and breast cancer: an epigenetic tale. J. Mammary Gland Biol. Neoplasia (2001) 6: 169-182.
54. TLSTY TD, CRAWFORD YG, HOLST CR et al.: Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol. Neoplasia (2004) 9: 263-274. (Pubitemid 39545743)
55. MULLER HM, WIDSCHWENDTER A, FIEGL H et al.: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. (2003) 63: 7641-7645. (Pubitemid 37466689)
56. HOQUE MO, FENG Q, TOURE P et al.: Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol. (2006) 24: 4262-4269. (Pubitemid 46630783)
57. SHARMA G, MIRZA S, PRASAD CP et al.: Promoter hypermethylation of p16(INK4A), p14(ARF), CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci. (2007) 80: 1873-1881. (Pubitemid 46562520)
58. KRASSENSTEIN R, SAUTER E, DULAIMI E et al.: Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin. Cancer Res. (2004) 10: 28-32. (Pubitemid 38114158)
59. COSTA VL, HENRIQUE R, JERONIMO C: Epigenetic markers for molecular detection of prostate cancer. Dis. Markers (2007) 23: 31-41. (Pubitemid 46333639)
60. KONISHI N, SHIMADA K, ISHIDA E et al.: Molecular pathology of prostate cancer. Pathol. Int. (2005) 55: 531-539. (Pubitemid 41725526)
61. PERRY AS, FOLEY R, WOODSON K et al.: The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer (2006) 13: 357-377. (Pubitemid 43886663)
62. CAIRNS P, ESTELLER M, HERMAN JG et al.: Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. (2001) 7: 2727-2730. (Pubitemid 32911377)
63. ROUPRET M, HUPERTAN V, YATES DR et al.: Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res. (2007) 13: 1720-1725. (Pubitemid 46952937)
64. GONZALGO ML, PAVLOVICH CP, LEE SM et al.: Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. (2003) 9: 2673-2677. (Pubitemid 36842112)
65. HOQUE MO, TOPALOGLU O, BEGUM S et al.: Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol. (2005) 23: 6569-6575. (Pubitemid 46190250)
66. JERONIMO C, USADEL H, HENRIQUE R et al.: Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology (2002) 60: 1131-1135. (Pubitemid 35447593)
67. GOESSL C, KRAUSE H, MULLER M et al.: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. (2000) 60: 5941-5945.
68. GOESSL C, MULLER M, HEICAPPELL R et al.: DNA-based detection of prostate cancer in urine after prostatic massage. Urology (2001) 58: 335-338. (Pubitemid 32816344)
69. SUH CI, SHANAFELT T, MAY DJ et al.: Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol. Cell Probes. (2000) 14: 211-217.
70. DACIC S: Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis. Expert Rev. Mol. Diagn. (2007) 7: 77-86. (Pubitemid 46115933)
71. KERR KM, GALLER JS, HAGEN JA et al.: The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis. Markers (2007) 23: 5-30. (Pubitemid 46333646)
72. TOYOOKA S, TOYOOKA KO, MARUYAMA R et al.: DNA methylation profiles of lung tumors. Mol. Cancer Ther. (2001) 1: 61-67.
73. TANAKA R, WANG D, MORISHITA Y et al.: Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer (2005) 103: 608-615.
74. SHAPIRO GI, PARK JE, EDWARDS CD et al.: Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. (1995) 55: 6200-6209.
75. SANCHEZ-CESPEDES M, DECKER PA, DOFFEK KM et al.: Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res. (2001) 61: 2092-2096. (Pubitemid 32692032)
76. LIU Y, LAN Q, SIEGFRIED JM et al.: Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia (2006) 8: 46-51.
77. BELINSKY SA, NIKULA KJ, PALMISANO WA et al.: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad Sci. USA (1998) 95: 11891-11896.
78. TSOU JA, SHEN LY, SIEGMUND KD et al.: Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer (2005) 47: 193-204. (Pubitemid 40082162)
79. ZHU WG, SRINIVASAN K, DAI Z et al.: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol. Cell Biol. (2003) 23: 4056-4065. (Pubitemid 36666412)
80. SORIA JC, RODRIGUEZ M, LIU DD et al.: Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. (2002) 62: 351-355. (Pubitemid 34106401)
81. LAI JC, CHENG YW, CHIOU HL et al.: Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer. Int. J. Cancer (2005) 117: 974-980.
82. CHEN Y, HUHN D, KNOSEL T et al.: Downregulation of connexin 26 in human lung cancer is related to promoter methylation. Int. J. Cancer (2005) 113: 14-21. (Pubitemid 39507305)
83. WISTUBA , II, GAZDAR AF, MINNA JD: Molecular genetics of small cell lung carcinoma. Semin. Oncol. (2001) 28: 3-13. (Pubitemid 32730372)
84. MIYAMOTO K, ASADA K, FUKUTOMI T et al.: Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-Osulfotransferase- 2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene (2003) 22: 274-280. (Pubitemid 36174184)
85. DU Y, CARLING T, FANG W et al.: Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res. (2001) 61: 8094-8099. (Pubitemid 33091596)
86. XU XL, WU LC, DU F et al.: Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res. (2001) 61: 7943-7949.
87. DAMMANN R, TAKAHASHI T, PFEIFER GP: The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene (2001) 20: 3563-3567. (Pubitemid 32619409)
88. OSADA H, TATEMATSU Y, YATABE Y et al.: Frequent and histological type-specific inactivation of 14-3-3 in human lung cancers. Oncogene (2002) 21: 2418-2424. (Pubitemid 34407301)
89. DAMMANN R, SCHAGDARSURENGIN U, SEIDEL C et al.: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol. Histopathol. (2005) 20: 645-663. (Pubitemid 40468282)
90. FUKASAWA M, KIMURA M, MORITA S et al.: Microarray analysis of promoter methylation in lung cancers. J. Hum. Genet. (2006) 51: 368-374.
91. BELINSKY SA, GRIMES MJ, CASAS E et al.: Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br. J. Cancer (2007) 96: 1278-1283. (Pubitemid 46625083)
92. PALMISANO WA, DIVINE KK, SACCOMANNO G et al.: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. (2000) 60: 5954-5958.
93. BELINSKY SA, KLINGE DM, DEKKER JD et al.: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin. Cancer Res. (2005) 11: 6505-6511. (Pubitemid 41338988)
94. RAMIREZ JL, SARRIES C, DE CASTRO PL et al.: Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. (2003) 193: 207-216. (Pubitemid 36428904)
95. MCLOUGHLIN RM, OMORAIN CA: Colorectal cancer screening. World J. Gastroenterol. (2006) 12: 6747-6750. (Pubitemid 44811393)
96. LYNCH JP, HOOPS TC: The genetic pathogenesis of colorectal cancer. Hematol. Oncol. Clin. North Am. (2002) 16: 775-810. (Pubitemid 35215825)
97. KONDO Y, ISSA JP: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. (2004) 23: 29-39. (Pubitemid 38221595)
98. GRADY WM, RAJPUT A, LUTTERBAUGH JD et al.: Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. (2001) 61: 900-902. (Pubitemid 32174399)
99. WALLNER M, HERBST A, BEHRENS A et al.: Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res. (2006) 12: 7347-7352. (Pubitemid 46095407)
100. LEUNG WK, TO KF, MAN EP et al.: Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol. (2005) 100: 2274-2279.
101. NAKAYAMA H, HIBI K, TAGUCHI M et al.: Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett. (2002) 188: 115-119. (Pubitemid 35292337)
102. NAKAYAMA H, HIBI K, TAKASE T et al.: Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int. J. Cancer (2003) 105: 491-493. (Pubitemid 36578552)
103. ZOU HZ, YU BM, WANG ZW et al.: Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. (2002) 8: 188-191.
104. BELSHAW NJ, ELLIOTT GO, WILLIAMS EA et al.: Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol. Biomarkers Prev. (2004) 13: 1495-1501. (Pubitemid 39202317)
105. LENHARD K, BOMMER GT, ASUTAY S et al.: Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin. Gastroenterol. Hepatol. (2005) 3: 142-149. (Pubitemid 40220309)
106. MULLER HM, OBERWALDER M, FIEGL H et al.: Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 363: 1283-1285. (Pubitemid 38496491)
107. BAI AH, TONG JH, TO KF et al.: Promoter hypermethylation of tumor-related genes in the progression of colorectal neoplasia. Int. J. Cancer (2004) 112: 846-853. (Pubitemid 39435270)
108. PETKO Z, GHIASSI M, SHUBER A et al.: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res. (2005) 11: 1203-1209. (Pubitemid 40175772)
109. COMPTON C, FENOGLIO-PREISER CM, PETTIGREW N et al.: American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer (2000) 88: 1739-1757. (Pubitemid 30183160)
110. HUANG ZH, LI LH, YANG F et al.: Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J. Gastroenterol. (2007) 13: 950-954. (Pubitemid 46470311)
111. CHEN WD, HAN ZJ, SKOLETSKY J et al.: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. (2005) 97: 1124-1132. (Pubitemid 41511211)
112. LEUNG WK, TO KF, MAN EP et al.: Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am. J. Gastroenterol. (2007) 102: 1070-1076. (Pubitemid 46698227)
113. HUANG Z, LI L, WANG J: Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig. Dis. Sci. (2007).
114. LEUNG WK, TO KF, MAN EP et al.: Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin. Chem. (2004) 50: 2179-2182. (Pubitemid 39425867)
115. BOSCH FX, RIBES J, DIAZ M et al.: Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 127: S5-S16. (Pubitemid 39423365)
116. MCGLYNN KA, LONDON WT: Epidemiology and natural history of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. (2005) 19: 3-23. (Pubitemid 40331495)
117. THORGEIRSSON SS, GRISHAM JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. (2002) 31: 339-346. (Pubitemid 35154440)
118. ZHU J: DNA methylation and hepatocellular carcinoma. J. Hepatobiliary Pancreat. Surg. (2006) 13: 265-273. (Pubitemid 44111333)
119. HERATH NI, LEGGETT BA, MACDONALD GA: Review of genetic and epigenetic alterations in hepatocarcinogenesis. J. Gastroenterol. Hepatol. (2006) 21: 15-21.
120. DAMMANN R, YANG G, PFEIFER GP: Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res. (2001) 61: 3105-3109. (Pubitemid 32691961)
121. WONG IH, LO YM, YEO W et al.: Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res. (2000) 6: 3516-3521.
122. WONG IH, LO YM, ZHANG J et al.: Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. (1999) 59: 71-73. (Pubitemid 29062959)
123. YEO W, WONG N, WONG WL et al.: High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. (2005) 25: 266-272.
124. ZHANG YJ, WU HC, SHEN J et al.: Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res. (2007) 13: 2378-2384. (Pubitemid 46698587)
125. PFEIFER GP, DAMMANN R: Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc) (2005) 70: 576-583. (Pubitemid 40920802)